Comparing PDGFC expression across a broader range of breast cancer molecular subtypes, as well as evaluating the activity of the PDGFC/NRG1 signaling axis between tumor cells and fibroblasts, will provide valuable insights for the development of more precise therapeutic strategies in breast cancer. This evidence concerns the gene NRG1 and breast cancer.